Ulixertinib

Clinical Trials Overview

2 trials found
About Ulixertinib

Ulixertinib is an oral ERK1/2 kinase inhibitor evaluated in colorectal cancer patients with BRAF mutations and EGFR-expressing tumors. The drug targets the downstream effectors of the MAPK pathway and has been studied in combination with cetuximab (an EGFR inhibitor) and encorafenib (a BRAF inhibitor) for unresectable or metastatic colorectal cancer. Clinical trials have focused on patients with advanced refractory solid tumors, including CRC with specific molecular profiles. Ulixertinib represents a targeted approach to inhibit tumor growth in cancers driven by MAPK pathway activation.

Category Targeted Therapy
Brand Name Not yet branded
Mechanism Ulixertinib selectively inhibits extracellular signal-regulated kinases 1 and 2 (ERK1/2), which are critical downstream effectors in the RAS/RAF/MEK/ERK signaling pathway. By blocking ERK1/2 activity, ulixertinib disrupts cellular proliferation, survival signals, and tumor growth in cancers with MAPK pathway hyperactivation.
med_trials_same_target
LY3214996 Other Medications · 2 trials
ERK1 ERK2
2
Total Trials
1
Recruiting
1
Active
0
Completed
6,479
Total Enrollment
3
Countries
med_trials_active_sites
Recruiting sites 3 countries
Phase:
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
NCT05985954 Phase 1 Recruiting 27 patients
Start: Jan 2024
End: Mar 2028
INTERVENTIONAL
Medications: Cetuximab Encorafenib Ulixertinib
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
United States
View Details ClinicalTrials.gov Am I eligible?
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060 Phase 2 Active 6,452 patients
Start: Aug 2015
End: Dec 2026
INTERVENTIONAL
Medications: Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib Fexagratinib Ipatasertib Larotrectinib Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Taselisib Trametinib Trastuzumab Ulixertinib Vismodegib
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, l...
United States, Guam, Puerto Rico
View Details ClinicalTrials.gov Am I eligible?
Back to Drug Glossary View All Trials Filter Recruiting Trials